Experts Highlight Need for Nutritional Support for Patients on Weight Loss Medications

Weight loss drugs like semaglutide and tirzepatide, known by brand names such as Ozempic, Wegovy, and Mounjaro, mimic the hormone GLP-1. These medications suppress appetite, enhance feelings of fullness, and reduce cravings, cutting calorie intake by 16-39%. However, there is limited research on their effects on diet quality, protein intake, and micronutrient adequacy. Notably, muscle can account for up to 40% of total weight lost during treatment.

Dr. Adrian Brown, corresponding author at the Centre of Obesity Research at UCL, emphasized that while these medications can significantly aid weight loss and improve health outcomes, a lack of nutritional support can compromise dietary quality. This situation may prevent patients from obtaining enough essential nutrients for their overall well-being.

Guidelines from the National Institute for Health and Care Excellence (NICE) recommend semaglutide for individuals with a BMI of at least 35.0 kg/m2 and accompanying health conditions, alongside a reduced-calorie diet and physical activity. However, most users—about 95% of the estimated 1.5 million users in the UK—obtain these medications privately and may not receive adequate nutritional advice.

Dr. Marie Spreckley of the MRC Epidemiology Unit at the University of Cambridge noted that even as the use of GLP-1 therapies has surged, the accompanying nutritional support has not evolved accordingly. Patients often lack structured dietary guidance while experiencing appetite suppression, which could lead to preventable health problems such as nutritional deficiencies and muscle loss.

Insufficient micronutrient intake can result in a variety of health issues, including fatigue, weakened immune response, hair loss, and osteoporosis. The researchers found only 12 relevant studies regarding nutrition and diet in the context of semaglutide or tirzepatide, which varied in their methods and lacked standardized approaches, making it challenging to derive effective support strategies.

Given the increasing reliance on these medications, the team advocates for improved nutritional guidance by drawing parallels with strategies used in weight loss surgery, which have demonstrated similar efficacy to GLP-1 drugs. Dr. Cara Ruggiero, co-author of the study, highlighted the necessity of prioritizing nutrient-dense foods and high-quality protein to help maintain muscle mass during periods of appetite suppression.

While the evidence does not support strict low-fat diets, some studies suggest that users of these treatments tend to consume high levels of total and saturated fats, indicating a need for personalized fat intake guidance. Additionally, although meal frequency was not a focus in most trials, small, frequent meals could alleviate side effects like nausea, especially in the early days of treatment.

The researchers are calling for more studies in this area and emphasize the importance of consulting with patients to identify the most meaningful types of support needed. They have initiated AMPLIFY, a project aimed at understanding the real-world experiences of those using these weight loss therapies.

Dr. Spreckley, leading AMPLIFY, stated that while these medications are changing obesity care, there is still much to learn about their effects on daily life, appetite, and well-being, particularly among underrepresented communities in obesity research.

Funding for this research was provided by the National Institute for Health and Care Research (NIHR), with further support from the Medical Research Council and the NIHR UCLH Biomedical Research Centre.